A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab
- 1 April 2015
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 14 (4) , 323-331
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Severe Multi-Resistant Pemphigus vulgaris: prolonged remission with a single cycle of RituximabAnais Brasileiros de Dermatologia, 2013
- Off-label use of rituximab in dermatology: pemphigus treatmentAnais Brasileiros de Dermatologia, 2013
- Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 PatientsDermatology, 2011
- A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceusJournal of the American Academy of Dermatology, 2011
- Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus VulgarisDermatology Research and Practice, 2010
- Pemphigus and infectious agentsAutoimmunity Reviews, 2008
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- Rituximab Therapy of Recalcitrant Bullous DermatosesJournal of Dermatological Case Reports, 2008
- Consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004